The short answer
Cascara can cause diarrhea and loss of fluid or electrolytes, especially with excessive or prolonged use. Becoming dehydrated while taking enalapril can increase the risk of low blood pressure and kidney problems. This is a conditional concern; the exact combination has not been measured in a clinical trial.
What this answer covers
Oral cascara bark from Frangula purshiana, synonymous with Rhamnus purshiana. Does not include Frangula alnus, senna, coffee-fruit cascara or unspecified multi-herb laxatives.
- Supplement or preparation
- cascara bark
- Medication ingredient
- enalapril
What connects cascara to enalapril safety?
The practical link is fluid loss. Cascara is a stimulant laxative, and diarrhea can leave you short of fluid and salts. Enalapril labeling warns that substantial fluid or salt depletion increases susceptibility to a large blood-pressure drop and kidney consequences. Applying these two warnings to co-use is a clinical precaution, not a measured risk estimate for the pair.
Does cascara lower potassium even though enalapril can raise it?
Prolonged laxative misuse can lower potassium. Enalapril can raise potassium, so the effects cannot be assumed to cancel each other. Kidney function, diarrhea and other medicines affect the result. Do not add potassium tablets or a potassium salt substitute to compensate without a clinician checking whether replacement is needed.
Does occasional use differ from daily use?
The European cascara monograph limits treatment of occasional constipation to no more than one week and advises investigating constipation that needs a laxative every day. Kidney disease, severe dehydration, higher doses and other medicines that affect electrolytes make review more important. These cautions concern medicinal bark preparations, not coffee products also called cascara.
Would taking the products at different times help?
No tested spacing interval was found for cascara and enalapril. Moving a dose to another hour does not correct diarrhea or fluid loss. If you develop persistent diarrhea or feel faint, contact your clinician for advice about the laxative, hydration and your prescription medicines. Blood pressure, kidney function and electrolytes may need reassessment.
Evidence and practical considerations
Side effects & toxicity
Cascara-associated diarrhea or substantial fluid loss can create the volume-depleted state in which enalapril is less well tolerated.
- Exact scope
- Oral cascara bark from Frangula purshiana, synonymous with Rhamnus purshiana. Does not include Frangula alnus, senna, coffee-fruit cascara or unspecified multi-herb laxatives. with Enalapril, exact RxCUI 3827, inventory name enalapril, TTY IN. The inspected enalapril maleate label explicitly identifies the maleate salt of enalapril and its hydrolysis to enalaprilat. This is the salt-to-IN bridge for oral tablets and solution. The solution label also includes tablet clinical data. Do not transfer these conclusions to injected enalaprilat, combination products, or other ACE inhibitors without a separate rationale.
- Medication form and route
- oral
- Timing or duration
- Concern increases with ongoing diarrhea or prolonged laxative use.
What remains uncertain
- Explicit inference from two official sources, not direct pair coadministration evidence. Risk is not established for every brief exposure.
Factors that may matter: diarrhea; prolonged or excessive use; kidney disease; other diuretics.
Read the supporting source summaries
Source 1: regulatory herbal assessment
ema.europa.eu · Source check Sep 10, 2026
Population: Adults and adolescents over 12 using standardized cascara bark preparations for occasional constipation.
Diarrhea can cause fluid and electrolyte loss. Severe dehydration is a contraindication. Kidney disease warrants attention to electrolyte imbalance. Long-term laxative abuse can lower potassium; diuretics, corticosteroids and licorice may increase the loss.
How this applies: Bark of Rhamnus purshiana, confirmed as a synonym of Frangula purshiana. The link to enalapril is specifically the established susceptibility to volume depletion, not shared potassium-lowering pharmacology.
The monograph does not name enalapril or quantify an exact-pair risk. Clinical experience and related anthranoid evidence inform the monograph; this is not a controlled enalapril-cascara study.
Source 2: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral enalapril for hypertension, heart failure or asymptomatic left ventricular dysfunction.
Warns that volume or salt depletion can produce excessive hypotension and renal consequences. Serum potassium should be monitored. Potassium supplements can cause hyperkalemia. Describes the maleate salt and conversion to enalaprilat.
How this applies: Applies to oral enalapril through the explicit maleate-to-enalapril bridge. Physiologic susceptibility is relevant when a botanical causes fluid loss or opposes blood-pressure control; this is an explicit clinical inference.
No named botanical interaction is measured. These medication-specific warnings establish susceptibility and monitoring context, not the incidence or magnitude of any botanical interaction.
Source 3: authoritative botanical taxonomy
powo.science.kew.org · Source check Sep 10, 2026
Population: Botanical nomenclature record, not human participants.
Accepts Frangula purshiana and lists Rhamnus purshiana as a homotypic synonym.
How this applies: Supplies the explicit species-name bridge needed to apply the EMA cascara bark monograph to this exact species record.
Taxonomic evidence only; it does not validate medicinal doses, products or clinical interactions. Other Frangula species are distinct.
Research assessment: · Open full citations ↗
Timing & monitoring
Electrolyte disturbances require clinical assessment; no evidence-based enalapril-cascara spacing interval was identified.
- Exact scope
- Oral cascara bark from Frangula purshiana, synonymous with Rhamnus purshiana. Does not include Frangula alnus, senna, coffee-fruit cascara or unspecified multi-herb laxatives. with Enalapril, exact RxCUI 3827, inventory name enalapril, TTY IN. The inspected enalapril maleate label explicitly identifies the maleate salt of enalapril and its hydrolysis to enalaprilat. This is the salt-to-IN bridge for oral tablets and solution. The solution label also includes tablet clinical data. Do not transfer these conclusions to injected enalaprilat, combination products, or other ACE inhibitors without a separate rationale.
- Medication form and route
- oral
- Timing or duration
- Monitor according to symptoms and clinical exposure, rather than a universal schedule.
What remains uncertain
- Cascara-related potassium loss must not be interpreted as a predictable reversal of enalapril-related hyperkalemia.
Factors that may matter: potassium supplements; kidney function; other electrolyte-active medicines.
Read the supporting source summaries
Source 1: regulatory herbal assessment
ema.europa.eu · Source check Sep 10, 2026
Population: Adults and adolescents over 12 using standardized cascara bark preparations for occasional constipation.
Diarrhea can cause fluid and electrolyte loss. Severe dehydration is a contraindication. Kidney disease warrants attention to electrolyte imbalance. Long-term laxative abuse can lower potassium; diuretics, corticosteroids and licorice may increase the loss.
How this applies: Bark of Rhamnus purshiana, confirmed as a synonym of Frangula purshiana. The link to enalapril is specifically the established susceptibility to volume depletion, not shared potassium-lowering pharmacology.
The monograph does not name enalapril or quantify an exact-pair risk. Clinical experience and related anthranoid evidence inform the monograph; this is not a controlled enalapril-cascara study.
Source 2: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral enalapril for hypertension, heart failure or asymptomatic left ventricular dysfunction.
Warns that volume or salt depletion can produce excessive hypotension and renal consequences. Serum potassium should be monitored. Potassium supplements can cause hyperkalemia. Describes the maleate salt and conversion to enalaprilat.
How this applies: Applies to oral enalapril through the explicit maleate-to-enalapril bridge. Physiologic susceptibility is relevant when a botanical causes fluid loss or opposes blood-pressure control; this is an explicit clinical inference.
No named botanical interaction is measured. These medication-specific warnings establish susceptibility and monitoring context, not the incidence or magnitude of any botanical interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and current official source documents inspected. Article distinguishes measured findings, preparation limits and remaining uncertainty. | |
| Research summary published |
Article revision: 6b103c140110206e
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.